[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"red-blood-cell-transfusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:red-blood-cell-transfusion":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100533775","the-effect-of-retrograde-autologous-priming-on-transfusion-requirements-after-cardiac-surgery-100533775",false,"NCT06230198","The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery","The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery (TheRAPy): a Multiple Period Vanguard Cluster Crossover Trial","TheRAPy","Inclusion Criteria:\n\n* Hospitals completing \\>200 adult cardiac surgical cases a year; (ii) 95% of cardiovascular surgery group (i.e., cardiac anesthesiologists, surgeons, and perfusionists) agree to manage patients under both autologous priming policies as per their randomization schedule for the duration of the trial.\n* All patients undergoing cardiac surgery on cardiopulmonary bypass at an enrolled site during the trial period will be included in data collection.\n\nExclusion Criteria:\n\n* Complete \\\u003C=200 cardiac surgical cases.\n* \\\u003C95% of their cardiovascular surgery group agrees to manage patients according to either of the two policies.",true,"ALL","10 Years","110 Years",{"count":22,"type":23},4500,"ESTIMATED","INTERVENTIONAL",[26],"NA","The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.",[29],"Red Blood Cell Transfusion","RECRUITING","2025-02-27",{"date":33,"type":34},"2025-03-04","ACTUAL",{"date":36,"type":34},"2024-12-04",{"date":38,"type":23},"2026-11",{"name":40,"class":41},"Population Health Research Institute","OTHER",4]